156 results about "Mrna level" patented technology

The invention discloses application of Lactobacillus reuteri CCFM1289 with high yield of indoleacetic acid in relieving anxiety and depression, and belongs to the technical field of microorganisms. The Lactobacillus reuteri CCFM1289 can produce heteroauxin at high yield in vivo and in vitro, promote the yield of heteroauxin in fecal flora, relieve anxiety-like and depression-like behaviors of depression mice, relieve HPA hyperfunction, improve the level of brain-derived neurotrophic factor BDNF in hippocampus, promote secretion of 5-HTP and 5-HT in brain, improve the content of heteroauxin in colon, serum and brain, and improve the content of heteroauxin in colon, serum and brain. The compound can be used for improving intestinal flora metabolism imbalance, improving mRNA levels of hippocampal neurogenin-2, synapsin and post-synaptic dense protein 95, maintaining neuronal synaptic function stability, activating AHR signal channels, improving bicortin DCX expression and promoting neurogenesis so as to relieve depression mood, and can be used for drugs, health care products or healthy food for preventing and treating depression.

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.

Provided is an siRNA for inhibiting the gene expression of complement factor B (CFB), or a pharmaceutical composition or conjugate containing the siRNA. The siRNA contains a sense strand and an antisense strand. Each nucleotide in the siRNA is an independent modified or unmodified nucleotide. The sense strand contains a segment of nucleotide sequence I, and the nucleotide sequence I and a nucleotide sequence show in SEQ ID NO: 1 have an equal length and differ by no more than 3 bases. The antisense strand contains a nucleotide sequence II, and the nucleotide sequence II and a nucleotide sequence shown in SEQ ID NO: 2 have an equal length and differ by no more than 3 bases. The siRNA or the pharmaceutical composition or conjugate containing the siRNA can effectively treat and / or prevent diseases related to the mRNA level of the gene expression of the CFB.

The invention discloses application of sauchinone in cardiac fibrosis, relates to the technical field of medicines, and particularly relates to application of pharmaceutically acceptable salt derivatives of sauchinone in preparation of medicines for treating and / or relieving cardiac fibrosis. The sauchinone disclosed by the invention inhibits proliferation and migration of fibroblasts induced by Ang II. The sauchinone has a potential anti-cardiac fibrosis effect. The sauchinone can reduce the area of cardiac fibrosis and down-regulate mRNA level and protein expression of fibrosis related indexes, so that the sauchinone shows a potential anti-fibrosis effect.

The present invention relates to an antisense long non-encoding RNA (aslncRNA) that may form a partial double stranded (ds) complex with a corresponding cellular mRNA in eukaryotic cells and to a biological complex comprising the antisense lncRNA and a target mRNA that may together form a partial double stranded complex in vitro. The dsRNA complex is preferentially exported from the nucleus and translated in the cytoplasm and thereby gene expression is boosted. In addition to boosting aslnc-RNAs inhibitiory aslnc RNAs are disclosed. An expression vector comprising a nucleic acid sequence of the aslncRNA is also disclosed. The present invention can be used to increase or decrease export of a target mRNA from the nucleus and thus, to increase or decrease gene expression without interfering with genomic DNA or with mRNA levels. Methods to increase or decrease the export and / or expression of a target mRNA, cell transfections using plasmids expressing the antisense lncRNA or using conjugates comprising the aslncRNA, and a pharmaceutical composition comprising the as-lncRNA are also disclosed. The aslncRNA, the complex, the expression vector, and the conjugate are useful for enhancing the production of recombinant proteins that are used in biotechnological applications and for medical purposes. The aslncRNA is also useful for increasing antigen presentation upon mRNA vaccination.

The invention discloses a primer and probe combination and method for detecting the content of vRNA, cRNA and mRNA of influenza viruses H7N9 in vivo and application of the primer and probe combination and method, and belongs to the technical field of biology. In order to solve the technical problem that the prior art can only detect vRNA, cRNA and mRNA of influenza viruses on in-vitro cell lines and cannot adapt to animal in-vivo infection experiments with complex template quantities, the invention designs a primer and probe combination for detecting in-vivo H7N9 influenza virus PB2 or NA gene vRNA, cRNA and mRNA. The primer and probe combination comprises a reverse transcription primer, a fluorescent quantitative PCR primer and a probe, the obtained primer and probe combination and a fluorescent quantitative PCR technology are utilized to measure the vRNA content, the cRNA content and the mRNA content of PB2 and NA genes of the H7N9 virus in a mouse body, and an experimental scheme is provided for researching the real copying condition of the influenza virus H7N9 in the body.

The invention discloses bifidobacterium bifidum and application of the bifidobacterium bifidum in relieving ovalbumin-induced food allergy, and belongs to the technical field of microorganisms. According to the invention, a strain of bifidobacterium bifidum CCFM1063 is screened out, and the bifidobacterium bifidum CCFM1063 has the effects of relieving weight loss and allergic symptoms of mice caused by OVA; according to the present invention, with the application of the loratadine, the high mMCP-1 level caused by OVA can be significantly reduced, the IgE level can be reduced, the mRNA level of the jejunum allergy related cytokines such as TSLP, IL-4 and IL-33 can be significantly reduced, and the partial effect is superior to the loratadine; when the bifidobacterium bifidum CCFM1063 is combined with breast milk oligosaccharide 3 '-SL, the bifidobacterium bifidum CCFM1063 has a synergistic effect on improving food allergy symptoms, and the effect of the bifidobacterium bifidum CCFM1063 is obviously superior to that of a single strain.

The invention discloses a construction method of a Csdc2 overexpression vector and an interference cell model, and belongs to the technical field of cell engineering and gene engineering. Csdc2 is found to be an important gene for regulating and controlling periodic development of hair follicles, and gene expression is acted by related hormones and participates in regulation and control of villus growth of down producing goats. The Csdc2 is taken as a research object, the Csdc2 gene is overexpressed through a gene engineering technology, and the Csdc2 in the dermal papilla cell of the down producing goat can be accurately overexpressed; the expression of the goat Csdc2 gene at the mRNA level can be effectively inhibited by acting the siRNA for inhibiting the expression of the goat Csdc2 gene on the dermal papilla cells of the down producing goat, and successful establishment of a Csdc2 overexpression vector and siRNA interference cell model is proved. The Csdc2 gene is helpful for researching the function of the Csdc2 gene, and has a good application value for researching the molecular mechanism of periodic growth of secondary hair follicles of down producing goats and regulating and controlling the growth of villus.

The present invention discloses an application of an insect virus FHV RNA1 replicon in exogenous gene amplification, wherein the application amplifies the exogenous gene at the mRNA level by utilizing the autonomous replication ability of the insect virus FHV RNA1 replicon; the present invention discloses a plasmid system based on the insect virus FHV RNA1 replicon and a method for constructing the plasmid system; the present invention also discloses a method and application of the plasmid system for expressing proteins in cells, wherein the plasmid system is used to obtain a cloning vector after double enzyme digestion, and after homologous recombination with an exogenous gene, the animal or plant protein is expressed in the cell.

The invention relates to application of a targeted intervention strategy based on a TRIM25-SNRK regulatory axis in treatment of non-small cell lung cancer. The nucleotide sequences of the mRNA of the TRIM25 gene and the mRNA of the SNRK gene are respectively as shown in SEQ ID NO.1 to SEQ ID NO.2. According to the invention, it is found for the first time that the combined targeting TRIM25-SNRK regulatory axis has a more significant cancer inhibition effect in the cell proliferation and migration process of the non-small cell lung cancer compared with single interference of TRIM25 expression level or transfection of exogenous SNRK mRNA expression plasmids. The siTRIM25 and SNRK-OE combination strategy designed by the invention can specifically knock down the level of TRIM25 mRNA and up-regulate the level of SNRK mRNA at the same time, and compared with the condition of singly transfecting siTRIM25 or SNRK-OE, a cell function experiment shows that the combination strategy has a more effective anti-tumor effect. Therefore, the TRIM25-SNRK regulation axis can be used as an intervention target to be applied to research, development and preparation of non-small cell lung cancer antitumor drugs.

The invention discloses application of KCNQ4 as a liver cancer diagnostic kit and in targeted drug development, and belongs to the field of biological medicine. Statistical analysis is carried out on the expression quantity of the KCNQ4 gene in liver cancer and normal liver tissues of a liver cancer patient in a TCGA database, and it is found that the expression quantity of the KCNQ4 gene in the liver cancer tissues is obviously higher than that of the KCNQ4 gene in the normal tissues. Secondly, an expression vector for interfering the KCNQ4 gene is utilized, and a large number of in-vitro cell experiments prove that interference on the expression level of the KCNQ4 gene can play a role in inhibiting proliferation and migration of liver cancer cells. The mRNA level of the genes CDK1 and CDK2 related to cell proliferation is inhibited, and it is proved from the molecular level of the genes that KCNQ4 can promote the occurrence of liver cancer, which prompts that KCNQ4 has good application in preparation of liver cancer diagnostic kits and targeted therapeutic drugs.

The present invention discloses an application of FN-1501 and its pharmaceutical composition in the preparation of drugs for preventing and / or treating liver injury, specifically including drugs for preventing and treating autoimmune hepatitis, viral hepatitis or drug-induced liver injury, especially drugs for preventing and treating autoimmune hepatitis. It can achieve multiple pharmacological effects of improving liver tissue structure damage, liver inflammation, reducing serum transaminase, serum lactate dehydrogenase and mRNA levels of inflammatory factors, and can play a therapeutic role at the gene level, molecular level and tissue level. There are no toxic side effects in the body, and the preparation form used is wide. The appropriate drug dosage form can be selected according to the clinical application scenario, which provides a new development strategy for targeted drugs for the prevention and treatment of liver injury.

The present invention relates to a composition, comprising neuropilin-1 (NRP-1) and / or a compound that maintains or upregulates intestinal epithelial NRP-1 protein levels and promotes Hedgehog (Hh) signaling in the intestinal epithelium for use in the prevention or treatment of a disease that is associated with a weakened intestinal barrier. Furthermore, the present invention relates to an in-vitro method for the detection of a weakened intestinal barrier in a mammal, comprising the steps of providing a sample of the intestinal epithelium from a donor mammal, measuring the protein or mRNA levels of epithelial neuropilin-1 (NRP-1) in epithelium cells isolated from said sample and correlating the observed NRP-1 levels with the levels observed in control samples from healthy donors, wherein lower NRP-1 levels in the sample from the donor mammal compared to the control samples indicate the presence or predisposition of a weakened intestinal barrier in said mammal.

The present invention relates to the application of targeting the HNRNPC-HNF1A regulatory axis in the treatment of non-small cell lung cancer. The HNRNPC-HNF1A regulatory axis includes the HNRNPC gene and the HNF1A gene, and the nucleotide sequences of the mRNA of the HNRNPC gene and the mRNA of the HNF1A gene are shown in SEQ ID NO.1 and SEQ ID NO.2 respectively. The present invention discovers for the first time that simultaneously targeting and intervening the key genes of the HNRNPC-HNF1A signaling pathway shows a more effective anti-proliferation and anti-metastasis effect on non-small cell lung cancer compared with separately inhibiting the expression levels of the HNRNPC or HNF1A gene. The present invention designs siRNA (siMIX) that can specifically and efficiently knockdown the mRNA levels of HNRNPC and HNF1A. The results of cell function experiments show that when the same dose of siRNA is transfected into non-small cell lung cancer cells, siMIX has a better anti-cell proliferation, migration and invasion effect than siHNRNPC or siHNF1A. Therefore, targeted inhibition of the HNRNPC-HNF1A pathway axis can be applied to the research and preparation of anti-tumor drugs for non-small cell lung cancer.

The invention provides a gene expression cassette for improving CsCE expression quantity and application. The gene expression cassette provided by the invention comprises a regulatory element and a target gene, the regulatory element comprises at least one of a coding sequence of dtRNA, a coding sequence of a signal peptide and a coding sequence of a fusion tag, and the target gene comprises a coding sequence of CsCE enzyme. Wherein the dtRNA contributes to keeping the structural stability when the CsCE enzyme is transcribed into mRNA, the signal peptide can promote the secretion of the CsCE enzyme, and the fusion tag can assist the correct folding of the CsCE enzyme, so that the expression of the CsCE enzyme can be synergistically regulated under the three-tube alignment of a DNA transcriptional mRNA layer, a protein secretion layer and a protein folding layer, the expression quantity of the CsCE enzyme can be effectively up-regulated, and the expression quantity of the CsCE enzyme can be effectively up-regulated. Therefore, the volume enzyme activity of the CsCE enzyme is improved, and the CsCE enzyme with higher volume enzyme activity can catalyze lactose to be converted into lactulose in the preparation of lactulose, so that the preparation yield of lactulose is improved.

The invention discloses a colorectal cancer diagnosis biomarker and application thereof. The biomarker is creatine kinase B (CKB). The invention proves that the expression of CKB in colorectal cancer tissues is obviously lower than that in paracancerous normal tissues, and the low expression of CKB is related to poor prognosis of patients. On the basis, the invention provides application of the CKB as the biomarker and a corresponding diagnostic kit. The kit can comprise an antibody or primer for detecting the CKB protein or mRNA level. The invention provides a new effective means for early diagnosis and prognosis of colorectal cancer.

The invention discloses a saRNA drug delivery system, which is composed of a saRNA drug and lipid nanoparticles, and the lipid nanoparticles are composed of ionizable cationic lipid, neutral phospholipid, sterol lipid and PEGylated phospholipid. The delivery system is stable in structure and good in dispersity, and can be prepared into an injection-grade nano preparation; meanwhile, saRNA medicine can be effectively delivered to a cell nucleus, the mRNA level of a target gene FXR is remarkably up-regulated, and a definite treatment effect is achieved.

The present invention relates to a therapeutic target for stem-like, epithelial-to-mesenchymal transition and mesenchymal (SEM) cancer subunits and an inhibitor thereof. In the present invention, on the basis of the fact that the intracellular concentration of ATP is high in SEM cancer subunits, a preparation for the prevention or treatment of gastric cancer can be effectively screened for by measuring the mRNA level of a gene encoding an ATP affinity protein or the expression level of the ATP affinity protein, information for predicting and diagnosing gastric cancer can be provided, a kit for diagnosing gastric cancer or predicting the prognosis thereof is provided, and a composition for diagnosing gastric cancer or predicting the prognosis thereof can be effectively provided.

This invention belongs to the field of biomedical technology and relates to a drug-loaded vesicle for promoting the healing of diabetic wounds. The drug-loaded vesicle has a core-shell structure. The core contains siRNA targeting ALKBH5 mRNA; the shell is a hybrid membrane of human umbilical vein endothelial cell membrane and milk-derived extracellular vesicle membrane, with its surface embedded with arginine-rich lipopeptides, and at least some arginine exposed outside the hybrid membrane. The core-shell structure effectively protects the siRNA from degradation and reduces off-target interference. The hybrid membrane shell has good biocompatibility, immunogenicity, and low cytotoxicity. The exposed arginine enhances tissue penetration and cellular uptake. In vitro and in vivo experiments have confirmed that this drug-loaded vesicle has good cellular uptake efficiency, effectively downregulates ALKBH5 expression, and restores mRNA levels. 6 A-modification increases the stability of C2orf69 mRNA, improves endothelial cell function, significantly promotes the healing of diabetic wounds, and has good biocompatibility and safety.

The application discloses application of a killer cell lectin-like receptor G1 (KLRG1) gene as a marker in preparation of a systemic lupus erythematosus (SLE) secondary hemophagocytic lymphohistiocytosis (HLH) detection preparation, and the preparation is used for detecting the expression level of the KLRG1 gene in a biological sample. Research finds that the expression level of the KLRG1 gene in SLE secondary HLH patients is significantly lower than that of healthy control groups and SLE patients, and has good diagnostic sensitivity and specificity. The application also discloses a preparation for detecting the expression level of the KLRG1 gene in a biological sample of a patient, the preparation contains a primer pair for detecting the mRNA level of the KLRG1 gene expression, or contains an antibody for detecting the protein level of the KLRG1 gene expression, and only needs to extract peripheral blood mononuclear cells (PBMC) after blood drawing to detect whether SLE patients are secondary to HLH, and the preparation is simple, rapid, and accurate in result.

The invention discloses an application of PINK1 in regulation and control of ER positive breast cancer tamoxifen drug resistance. The invention relates to application of PINK1 as a biomarker in evaluating the tamoxifen resistance of ER positive breast cancer cells. The drug resistance is evaluated by detecting the expression level of PINK1 in a sample and combining mitochondrial autophagy activity. The expression level of the PINK1 comprises an mRNA level and / or a protein level. According to the invention, the drug resistance formation process is systematically analyzed from the perspective of quality control of an organelle of mitochondrial autophagy, and through public database analysis and experimental verification, the overall up-regulation of the mitochondrial autophagy pathway in drug-resistant cells is clearly revealed, and the drug-resistant phenotype is promoted by maintaining the mitochondrial steady state, thereby opening up a new direction for understanding the drug-resistant mechanism.

The application discloses application of miRNA-23c as a gene targeting METTL3 in preparation of a medicine for preventing or treating bladder cancer. The application discloses a miRNA for inhibiting growth of bladder cancer, the miRNA-23c is complementary to the 3'-UTR of the mRNA of the METTL3 gene, can inhibit translation of the mRNA of a target gene or directly degrade the mRNA of the target gene. Fluorescent luciferase reporter gene analysis in an EJ cell line verifies that the METTL3 is a target gene of the miRNA-23c, then overexpression of the miRNA-23c in the EJ cell line finds that the miRNA-23c significantly down-regulates the mRNA level of the METTL3. The application first reports that the METTL3 can be a target gene of the miRNA-23c. The application provides certain application value in the aspect of using the miRNA as a drug target point for bladder cancer treatment.

The invention discloses siRNA (small interfering Ribonucleic Acid) of targeted bone morphogenetic protein 2, modified siRNA and application of the siRNA. According to the invention, siRNA drug design is carried out by taking the BMP2 gene as a target gene to obtain a series of siRNAs, siRNAs capable of effectively silencing the mRNA expression level of the BMP2 gene are screened from the siRNAs, and part of siRNA sequences can even silence the mRNA level of the BMP2 gene to about 25%. The siRNA sequence is further modified, wherein phosphorylation or phosphorylation analogue modification, skeleton modification, sugar ring modification and basic group modification are carried out on the 5'terminal of the sequence, or cholesterol molecule modification is carried out on the end group of the siRNA. The siRNA sequence is further subjected to cholesterol modification to obtain a human-mouse homologous sequence of the targeted BMP2 gene, and the in-vivo silencing activity of the BMP2 target spot is further researched in a mouse experimental model subsequently.

The invention provides an establishment method and application of a Zika virus infectious animal model, and belongs to the technical field of biology. According to the invention, ZIKV is inoculated to Toll-like receptor-deleted animals, such that the ZIKV challenging animal model is obtained. After the animal is inoculated with ZIKV, obvious ZIKV load can be detected in blood, liver, spleen, reproductive organ and brain tissue of the animal, moreover, the spleen is obviously swollen, the liver tissue has punctiform necrotic lesion, the splenosome is obviously reduced, and the mRNA level of inflammation related indexes Ccl5, Cxcl1, Isg15 and Isg56 is obviously up-regulated, which indicates that the ZIKV challenge model disclosed by the invention is successfully constructed; the method can be used in related researches such as ZIKV infection mechanism, vaccine research and development, anti-ZIKV drug research and development and the like.

This invention belongs to the field of cell detection technology, specifically involving the application of NR4A1 as an early biomarker for gamma-ray radiation. This invention discovers that in the early stage (2 hours) after gamma-ray radiation, the protein and mRNA levels of NR4A1 are significantly increased, exhibiting a radiation dose-dependent effect. NR4A1 can serve as a 2-hour biomarker for gamma-ray irradiated HeLa cells, allowing for the screening of cells irradiated for 2 hours, differentiating the duration of gamma-ray irradiation, and achieving early diagnosis of cellular gamma-ray radiation.

The invention belongs to the technical field of biological medicines, and discloses application of a CCT6A inhibitor in preparation of a medicine for treating colorectal cancer. CCT6A is determined to be a key cancer promoting gene of colorectal cancer for the first time, the CCT6A is remarkably and highly expressed in colorectal cancer tissues and cell lines, and high expression indicates poor prognosis of patients, so that a brand-new specific target is provided for targeted therapy of colorectal cancer. The invention discloses the cancer promoting effect of the compound in colorectal cancer and the association with 5FU drug resistance for the first time, enriches the development of colorectal cancer and the molecular mechanism research of chemotherapy drug resistance, and provides a new theoretical basis and research direction for the fundamental research in the field. Experiments prove that the inhibitor can significantly reduce the mRNA level of CCT6A in colorectal cancer cells so as to strongly inhibit tumor cell proliferation and increase the sensitivity of the colorectal cancer cells to 5-FU, and a novel therapeutic drug with high specificity and high curative effect is provided for treatment of colorectal cancer.

The present disclosure relates to alternative methods of conducting standard blood chemistry tests, the methods typically comprising: extracting an RNA from a blood sample, determining a mRNA level of a predictive gene in the blood sample, and converting the mRNA level of the predictive gene into the blood test result of the target blood component. The present disclosure also relates to blood test for performing the proxy methods. The blood test includes a plasmid with at least an exon of a predictive gene, a reagent for detecting a mRNA level of the predictive gene, and a reagent for detecting a mRNA level of a housekeeping gene.

Provided is a compact RNA-editing platform engineered from IscB, which has comparable or higher activity than Cas13, but with less or no cytotoxicity. IscB, has intrinsic affinity for complementary single-stranded (ss)DNA and RNA. This activity becomes dominant when its dsDNA binding activity is switched off, through the deletion or mutation of its Target Adjacent Motif domain, resulting in a modified IscB. The resulting R-IscB is comparable or better than Cas13, can efficiently alter splicing outcomes in human cells, and can mediate trans-splicing to correct mutations at the mRNA level. R-IscB also drives efficient A-to-I editing on mRNA when fused to ADAR2 and mediates cleavage-based mRNA knockdown upon HNH engineering. The same approach converts some Cas9s to RNA-targeting tools.

The invention discloses a plant-derived HTR3A antagonist and application thereof in preparation of a medicine for treating rosacea, and belongs to the field of biological medicines.The plant-derived HTR3A antagonist is screened aiming at HTR3A targets, and finally four compounds (D, H, E and T respectively) with high affinity with HTR3A are obtained; under a rosacea model constructed by THP-1 cells stimulated by LL-37 and neurotransmitter 5-HT (L5), through mRNA level detection of HTR3A and further verification and screening of an immunofluorescent staining experiment, the compounds D and T are determined to have remarkable effects. The invention provides a novel plant source compound and a regulation scheme for treating nervous rosacea, and has important application value.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.